Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Carmoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 20/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 18/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carmoterol SCHEMBL4360089 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL29355060 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494473 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL364838 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494299 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494565 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL11912044 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL5990417 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL465645 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1 | |
| Carmoterol SCHEMBL10494358 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2019-04-11 | — | — | US | claimed |
| EP-3238708-A1 | INHALANT FORMULATION CONTAINING CYCLODEXTRIN AND CORTICOSTEROID | CyDex Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | claimed |
| EP-1732512-B1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX PHARMACEUTICALS INC (US) | 2017-03-22 | — | — | EP | claimed |
| US-20090280067-A1 | CRYSTAL FORM OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-11-12 | — | — | US | claimed |
| US-20090280068-A1 | POLYMORPH OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-11-12 | — | — | US | claimed |
| EP-2116537-A1 | Polymorph of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone monohydrochloride | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-11-11 | — | — | EP | claimed |
| EP-2116536-A1 | Crystal form of 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1h)- quinolinone monohydrochloride | CHIESI FARMACEUTICI S.p.A. (IT) | 2009-11-11 | — | — | EP | claimed |
| US-20090263488-A1 | PRESSURISED METERED DOSE INHALERS CONTAINING SOLUTIONS OF BETA-2 AGONISTS | CHIESI FARMACEUTICI S.P.A. (IT) | 2009-10-22 | — | — | US | claimed |
| EP-1732512-A4 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX INC (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1729724-A4 | INHALENT FORMULATION CONTAINING SULFOALKYL ETHER GAMMA-CYCLODEXTRYN AND CORTICOSTEROID | CYDEX INC (US) | 2008-07-23 | — | — | EP | claimed |
| US-20070020299-A1 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | claimed |
| US-20070020298-A1 | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid | CYDEX PHARMACEUTICALS, INC. | 2007-01-25 | — | — | US | claimed |
| EP-1732512-A2 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | Cydex Inc. (US) | 2006-12-20 | — | — | EP | claimed |
| EP-1729724-A1 | INHALENT FORMULATION CONTAINING SULFOALKYL ETHER GAMMA-CYCLODEXTRYN AND CORTICOSTEROID | Cydex Inc. (US) | 2006-12-13 | — | — | EP | claimed |
| US-20060193785-A1 | Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent | CHIESI FARMACEUTICI S.P.A. (IT) | 2006-08-31 | — | — | US | claimed |
| WO-2005065435-A2 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | CYDEX, INC. ET AL. (US) | 2005-07-21 | — | — | WO | claimed |
| WO-2005065649-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER Ϝ-CYCLODEXTRIN AND CORTICOSTEROID | CYDEX, INC. (US) | 2005-07-21 | — | — | WO | claimed |
| US-20050154013-A1 | Pressurised metered dose inhalers containing solutions of beta-2 agonists | CHIESI FARMACEUTICI S.P.A. (IT) | 2005-07-14 | — | — | US | claimed |
| US-20040023935-A1 | Inhalation compositions, methods of use thereof, and process for preparation of same | DEY, L.P. | 2004-02-05 | — | — | US | claimed |
| US-6624181-B1 | Synergistic combination | ALTANA PHARMA AG (DE) | 2003-09-23 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090263488-A1 | PRESSURISED METERED DOSE INHALERS CONTAINING SOLUTIONS OF BETA-2 AGONISTS | ADRB2, ADRA2A, ADRA1D | ADRB2 1/4885ADRB1 7/4885 |
| US-20040023935-A1 | Inhalation compositions, methods of use thereof, and process for preparation of same | IL5, CHRM3, NOX5 | ADRB2 19/4885ADRB1 24/4885 |
| US-20090280067-A1 | CRYSTAL FORM OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE | CYP8B1, HTR2C, HTR1D | ADRB2 1408/4885ADRB1 1063/4885 |
| US-20070020298-A1 | Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid | STS, RORC, HSD11B1 | ADRB2 443/4885ADRB1 250/4885 |
| US-20190105404-A1 | INHALANT FORMULATION CONTAINING SULFOALKYL ETHER CYCLODEXTRIN AND CORTICOSTEROID | STS, SAE1, PDCD2L | ADRB2 1076/4885ADRB1 805/4885 |
| US-20070020299-A1 | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid | STS, SAE1, PDCD2L | ADRB2 1076/4885ADRB1 805/4885 |
| US-20090280068-A1 | POLYMORPH OF 8-HYDROXY-5-[(1R)-1-HYDROXY-2-[[(1R)-2-(4-METHOXYPHENYL)-1-METHYLETHYL]AMINO]ETHYL]-2(1H)-QUINOLINONE MONOHYDROCHLORIDE | UGT1A8, HTR1D, UGT1A1 | ADRB2 651/4885ADRB1 492/4885 |
| US-20060193785-A1 | Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent | HSD17B7, HSD17B1, CYP17A1 | ADRB2 169/4885ADRB1 143/4885 |
| US-20050154013-A1 | Pressurised metered dose inhalers containing solutions of beta-2 agonists | ADRB2, ADRA2A, ADRA1D | ADRB2 1/4885ADRB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.